The global lung cancer genomic testing market is witnessing substantial growth due to the increasing prevalence of lung cancer, rising adoption of precision medicine, and growing demand for personalized cancer treatment strategies. The global lung cancer genomic testing market size was valued at USD 1.41 billion in 2025 and is projected to grow from USD 1.53 billion in 2026 to USD 2.83 billion by 2034, registering a CAGR of 8% during the forecast period (2026–2034).

The market is expanding as healthcare providers increasingly incorporate genomic profiling into routine cancer care. Genomic testing enables the identification of specific genetic mutations and biomarkers that help physicians select targeted therapies, improving treatment outcomes and patient survival rates. Advancements in next-generation sequencing (NGS), liquid biopsy technologies, and molecular diagnostics are further supporting market growth worldwide.

Market Drivers

One of the primary factors driving the lung cancer genomic testing market is the rising incidence of lung cancer globally. Smoking, air pollution, occupational exposure to carcinogens, and genetic predisposition continue to increase the burden of lung cancer, creating strong demand for advanced diagnostic solutions.

Another significant growth driver is the increasing adoption of precision medicine. Genomic testing helps identify actionable mutations such as EGFR, ALK, KRAS, ROS1, RET, and MET, enabling physicians to prescribe targeted therapies that offer improved efficacy and reduced side effects.

The rapid advancement of next-generation sequencing technologies is also contributing to market growth. NGS platforms enable comprehensive genomic profiling, allowing multiple biomarkers to be analyzed simultaneously with high accuracy and efficiency.

Furthermore, increasing investments in oncology research, cancer screening programs, and personalized healthcare initiatives are creating new growth opportunities for market participants.

Market Challenges

Despite favorable growth prospects, the lung cancer genomic testing market faces several challenges. One major restraint is the high cost associated with advanced genomic testing procedures and sequencing technologies, which may limit accessibility in developing regions.

Another challenge is the shortage of skilled professionals required to perform, analyze, and interpret complex genomic testing results.

Additionally, reimbursement limitations, data management complexities, and regulatory requirements may hinder the widespread adoption of genomic testing services.

Market Segmentation

By Type

• Products
• Services

The products segment holds a significant market share due to increasing demand for genomic testing kits, sequencing instruments, and molecular diagnostic reagents.

By Technology

• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Fluorescence In Situ Hybridization (FISH)
• Immunohistochemistry (IHC)
• Others

The next-generation sequencing segment dominates the market owing to its ability to analyze multiple genetic alterations simultaneously and support comprehensive cancer profiling.

By Sample Type

• Tissue Biopsy
• Liquid Biopsy

The tissue biopsy segment accounts for the largest market share due to its established role as the standard approach for tumor genetic analysis. However, liquid biopsy is witnessing rapid adoption because of its minimally invasive nature.

By End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Research Organizations
• Academic Institutes

The hospitals and clinics segment represents a significant market share due to increasing integration of genomic testing into routine oncology care and treatment planning.

Regional Insights

North America

North America dominates the global lung cancer genomic testing market due to advanced healthcare infrastructure, strong adoption of precision medicine, significant oncology research investments, and the presence of leading genomic testing companies. The United States remains the largest contributor to regional growth.

Europe

Europe represents a significant market supported by increasing cancer awareness, expanding access to molecular diagnostics, and growing investments in personalized medicine initiatives.

Asia-Pacific

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to rising lung cancer incidence, improving healthcare infrastructure, increasing government support for cancer diagnostics, and growing adoption of genomic technologies across China, India, Japan, and South Korea.

Latin America, Middle East, and Africa

These regions are emerging markets driven by improving healthcare access, increasing cancer screening programs, and growing investments in advanced diagnostic technologies.

Key Players Analysis

The lung cancer genomic testing market is highly competitive, with leading companies focusing on technological innovation, strategic partnerships, and expansion of genomic testing portfolios to strengthen their market positions. Key companies operating in the market include:

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Guardant Health, Inc.
• NeoGenomics Laboratories
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings (LabCorp)
• Abbott Laboratories

These companies continue investing in advanced sequencing technologies, liquid biopsy platforms, AI-driven genomic analysis tools, and precision oncology solutions to address the growing demand for personalized lung cancer diagnosis and treatment.

For Detailed Insights, Visit:

https://straitsresearch.com/report/lung-cancer-genomic-testing-market

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.

Contact Us

Email: sales@straitsresearch.com

Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)